Geneus Technologies Secures New Round of Funding with CEC Capital as Exclusive Financial Advisor

Recently, Geneus Technologies, a leading domestic company in nanopore sequencing technology, announced the completion of a nearly RMB 100 million B++ round of financing. This round of funding was led by CDBT Group, with participation from Si Chuan Venture Capital. The raised capital will be used to accelerate the commercialization of the world's first "Single-base Nanopore Sequencing" (SNS) technology platform, promoting its large-scale application in clinical diagnostics, research services, and public health.

CEC Capital served as the exclusive financial advisor to Geneus Technologies in this transaction.

Geneus Technologies: Creator of the World's First SNS Sequencing Platform

Founded in 2017, Geneus Technologies focuses on the research, development, and industrial application of the SNS sequencing technology route with independent intellectual property rights. The company is committed to providing high-precision, low-cost, fully automated decentralized gene testing solutions to clients across various fields. In 2024, the company launched the world's first commercial sequencing platform based on SNS technology, the G-seq500, which began large-scale commercial use in Q4, marking China's "overtaking on the curve" in the field of fourth-generation sequencing technology.